Navigation Links
ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
Date:2/5/2008

WELLESLEY HILLS, Mass., Feb. 5 /PRNewswire/ -- Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced today that The Committee for Orphan Drug Products of the European Medicines Agency (EMEA) has granted Orphan Drug Designation for M40403 for the prevention of oral mucositis (OM) in head and neck cancer patients receiving radiotherapy.

The development of oral mucositis during radiation therapy of head and neck cancers is the major reason for poor compliance with and early discontinuation of radiation therapy by patients being treated for their condition.

European Union Orphan Drug Designation was designed to encourage the development of products that demonstrate promise for the diagnosis, prevention and/or treatment of life-threatening or very serious conditions that are rare and affect not more than 5 in 10,000 persons in the European Union. Orphan Drug Designation provides an important economic incentive for the development of new products in the cancer field. EU Orphan Designation provides for 10 years of market exclusivity, reduction in EU regulatory fees, and additional regulatory support for R&D initiatives.

ActivBiotics has also applied for Orphan Drug Designation with the U.S. Food and Drug Administration.

About M40403

This investigational small molecule mimics the action of a natural component of the cells, an enzyme called superoxide dismutase. Superoxide dismutase is thought to have a double effect, first through the reduction of inflammation, and secondarily through the decreased rate of programmed cell death (apoptosis). As mucositis involves inflammation, the positive effect of the M40403 over this process is expected to have a beneficial effect in the condition. M40403 has shown efficacy in an animal model where oral mucositis was induced by acute irradiation. The compound has been evaluated in approximately 700 subjects in several Phase I and II clinical trials, and was
'/>"/>

SOURCE ActivBiotics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
6. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
7. CryoCor Receives FDA Approval for Right Atrial Flutter
8. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
9. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
10. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
11. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)... A study published in the,scientific journal Natur...rted that InVitria,s ( http://www.InVitria.com ) C...effective replacement to bovine serum albumin,in E...d state of embryonic stem cell,self-renewal," disc...nant,albumin in place of animal-derived serum to e...
(Date:10/7/2008)...ligen Therapeutics Inc.,today announced that in vi...dates were presented at the XXII International Com...ighlighted the candidates, efficacy in,several ani...se highlighted presentations, as well as several i...l the deep expertise and expanding,knowledge base ...
(Date:10/7/2008)...g-term benefits and value in,moderate to severe Cr...ge,of Gastroenterology (ACG), ORLANDO, Fla. Oct. ...presented this week by UCB at the American College...ate that CIMZIA(R) (certolizumab pegol) - the,only...lpha) - provides,sustained improvement in symptoms...
(Date:10/7/2008)... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) announce...and Highly Selective MEK1/2 Inhibitor is Beneficia...ic Colitis in Mice," was presented at the,American...ting in Orlando,Florida. The poster, which provid...ompany,s lead mitogen-activated ERK kinase (MEK) i...
Breaking Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Philadelphia Insurance Companies Launches Home Health Care and Hospice Products 20892 1Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 1Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 2Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 3Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 5Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 6Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 7Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 8Breast Feeding More Protective for Girls Than Boys 20888 1Breast Feeding More Protective for Girls Than Boys 20888 2Boca Pharmacal Receives FDA Approval for Carbinoxamine Maleate 4 mg Tablet 20882 1
(Date:10/7/2008)...han 4,300 Activity Bags Donated to Area Youth in H...nio, HOUSTON, Oct. 7 /PRNewswire/ -- Carlson Hote...ether to provide more than 1,900 activity bags,to ... area. The tote bags,contained a fun activity book...., (Photo: http://www.newscom.com/cgi-bin/prnh/2...
(Date:10/7/2008)...N, N.J., Oct. 7 /PRNewswire-FirstCall/ -- Majesco ...ive provider of video games for the mass,market, t...matum 2009 has,gone gold and is scheduled to ship ... of its kind to integrate a celebrity fitness trai... life coach on the popular television,series "The ...
(Date:10/7/2008)...Y, France, October 7 /PRNewswire-FirstCall/ -- Sta...red into an exclusive agreement with,Catalent for ...line,autoinjector, ADREFLEX(R), co-developed and c...LC., ADREFLEX(R) consists of a syringe pre-filled...t and paediatric use (0.3 and 0.15 mg), in an,auto...
(Date:10/7/2008)...LAND, Oct. 7 /PRNewswire/ -- Cleveland Medical Dev... $1.23 million in NIH SBIR,FastTrack funding from ...une(TM), a system to augment stimulator programmin...arkinson,s disease (PD). CleveMed is,collaborating...storation of,the Cleveland Clinic Foundation, a wo...
Breaking Medicine News(10 mins):Health News:Carlson Hotels Worldwide Partners With the American Red Cross in Texas to Provide Relief for Children Affected by Hurricane Ike 2Health News:Majesco Entertainment and Interactive Game Group Announce 'Jillian Michaels' Fitness Ultimatum 2009' Ships to Stores October 21st 2Health News:Majesco Entertainment and Interactive Game Group Announce 'Jillian Michaels' Fitness Ultimatum 2009' Ships to Stores October 21st 3Health News:Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe 2Health News:CleveMed Receives $1.23 Million in NIH Funding to Develop a System to Augment Deep Brain Stimulation Programming in Parkinson's Disease 2
...er of the Bernhard Nocht Institute for Tropical Me...arial //parasite avoids the immune system by killi...s known that after infecting man, malarial parasit...ct the red blood cells, but it was not known how t...
...sity, University of California-Davis and Justus-Li...treatments //could be possible for autism and Park...focused their attention despite being distracted u...t a measure of cognitive deficit in mice that is r...
... are born infected with human cytomegalovirus, or ...anent disabilities due to the virus – almost one a...oss, vision loss, mental disability, a lack of coo... for Disease Control and Prevention, CMV is as com...
...from infection causing agents. Regulatory T-cells,...s of life itself to recognize// the invaders and d...ese cells seem to protect certain bacteria, viruse...ical college of Georgia, studied the T-cells in th...
Other Medicine News:Health News:Scientist Study New Treatment Modality for Psychiatric Disorders Using Mice 2Health News:Scientist Study New Treatment Modality for Psychiatric Disorders Using Mice 3Health News:Innovative Method for Creating a Human Cytomegalovirus Vaccine Outlined 2Health News:Regulatory T-cells – Protector or Cause of Diseases 2Health News:Regulatory T-cells – Protector or Cause of Diseases 3
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish.
Narrow 4 mm long smooth platform. Serrated handle with polished finish.
1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish.
Oval solid 16 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Serrated handle with locking thumb screw and polished finish.
Medicine Products: